Assenagon Asset Management S.A. Purchases 3,474 Shares of Qiagen (NYSE:QGEN)

Assenagon Asset Management S.A. increased its holdings in shares of Qiagen (NYSE:QGEN) by 39.9% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 12,184 shares of the company’s stock after acquiring an additional 3,474 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Qiagen were worth $550,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Nuance Investments LLC increased its holdings in shares of Qiagen by 17.3% in the second quarter. Nuance Investments LLC now owns 5,271,494 shares of the company’s stock worth $216,606,000 after acquiring an additional 778,005 shares in the last quarter. Earnest Partners LLC grew its position in shares of Qiagen by 11.1% in the 2nd quarter. Earnest Partners LLC now owns 3,807,284 shares of the company’s stock valued at $156,441,000 after purchasing an additional 379,679 shares during the period. DekaBank Deutsche Girozentrale increased its stake in Qiagen by 12.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 3,248,354 shares of the company’s stock worth $133,292,000 after purchasing an additional 353,280 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in Qiagen by 16.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,320,088 shares of the company’s stock worth $105,726,000 after purchasing an additional 324,417 shares in the last quarter. Finally, Sei Investments Co. raised its holdings in Qiagen by 19.7% during the 2nd quarter. Sei Investments Co. now owns 1,696,319 shares of the company’s stock worth $69,702,000 after buying an additional 278,930 shares during the period. 70.00% of the stock is currently owned by institutional investors.

Qiagen Stock Performance

Shares of NYSE QGEN opened at $43.08 on Monday. The stock has a market capitalization of $9.83 billion, a PE ratio of 143.35, a price-to-earnings-growth ratio of 3.21 and a beta of 0.41. Qiagen has a 52 week low of $37.51 and a 52 week high of $47.44. The stock has a 50 day moving average price of $44.22 and a 200 day moving average price of $43.61. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on QGEN. HSBC downgraded shares of Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective for the company. in a research report on Thursday, October 17th. Hsbc Global Res raised Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, Robert W. Baird boosted their price target on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $50.88.

About Qiagen

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.